Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315).

Autor: Sebastian M; Department of Medicine II, Hematology/Oncology, University Hospital Frankfurt, Frankfurt, Germany.; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt, Germany.; Frankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt, Germany., Eberhardt WEE; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.; Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen-Ruhrlandklinik, Essen, Germany., von der Heyde E; Onkologische Schwerpunktpraxis, Hannover, Germany., Dörfel S; Onkozentrum Dresden/Freiberg, Dresden, Germany., Wiegand J; Gemeinschaftspraxis für Hämatologie & Onkologie, Moers, Germany., Schiefer C; Pneumologie Markkleeberg GbR, Markkleeberg, Germany., Losem C; TZN-Tumorzentrum Niederrhein GmbH, Neuss, Germany., Jänicke M; Clinical Epidemiology and Health Economics, iOMEDICO, Freiburg i. Br, Germany., Fleitz A; Clinical Epidemiology and Health Economics, iOMEDICO, Freiburg i. Br, Germany., Zacharias S; Biostatistics, iOMEDICO, Freiburg i. Br, Germany., Kaiser-Osterhues A; Medical Department, iOMEDICO, Freiburg i. Br, Germany., Hipper A; AIO-Studien-gGmbH, Berlin, Germany., Dietel C; AIO-Studien-gGmbH, Berlin, Germany., Bleckmann A; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Benkelmann R; Innere Medizin/Hämatoonkologie/Gastroenterologie/Palliativmedizin, I. Med. Klinik, Konstanz, Germany., Boesche M; Pneumologie, Klinik für Innere Medizin B, Universitätsmedizin Greifswald, Greifswald, Germany., Grah C; Pneumologie-Lungenkrebszentrum, Gemeinschaftskrankenhaus Havelhöhe, Berlin, Germany., Müller A; Marienhof Koblenz, Katholisches Klinikum Koblenz Montabaur, Koblenz, Germany., Griesinger F; Department of Hematology and Oncology, University Department Internal Medicine-Oncology, Pius-Hospital, University Medicine Oldenburg, Oldenburg, Germany., Thomas M; Department of Thoracic Oncology, Thoraxklinik, University Hospital Heidelberg and Translational, Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.

Publikováno v: International journal of cancer [Int J Cancer] 2024 Jun 01; Vol. 154 (11), pp. 1967-1978. Date of Electronic Publication: 2024 Feb 08.

Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.

Autor: Koschmieder S; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany. skoschmieder@ukaachen.de.; Center for Integrated Oncology, Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany. skoschmieder@ukaachen.de., Isfort S; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.; Center for Integrated Oncology, Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany., Schulte C; Gemeinschaftspraxis Für Hämatologie Und Onkologie, Dortmund, Germany., Jacobasch L; Gemeinschaftspraxis Hämatologie - Onkologie, Dresden, Germany., Geer T; Medizinische Klinik III, Diakonie-Klinikum Schwäbisch Hall, Schwäbisch Hall, Germany., Reiser M; Praxis Internistischer Onkologie Und Hämatologie, Cologne, Germany., Koenigsmann M; Onkologisches Ambulanzzentrum (OAZ) Hannover, Hannover, Germany., Heinrich B; Hämatologisch-Onkologische Praxis Heinrich/Bangerter, Augsburg, Germany., Wehmeyer J; Gemeinschaftspraxis Für Hämatologie Und Onkologie, Münster, Germany., von der Heyde E; Onkologische Schwerpunktpraxis Dres. Ingo Zander und Eyck von der Heyde, Hannover, Germany., Tesch H; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt/Main, Germany., Gröschl B; Providing services for Novartis Pharma GmbH, Nürnberg, Germany., Bachhuber P; Novartis Pharma GmbH, Nürnberg, Germany., Großer S; Novartis Pharma GmbH, Nürnberg, Germany., Pahl HL; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. heike.pahl@klinikum.unifreiburg.de.

Publikováno v: Annals of hematology [Ann Hematol] 2023 Dec; Vol. 102 (12), pp. 3383-3399. Date of Electronic Publication: 2023 Oct 04.

873P Nivolumab (NIVO) in the first-line (1L) or second-line (2L) and later (2L+) settings in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from the German non-interventional study (NIS), HANNA

Autor: Dietz, A., Hahn, D.A., Langer, C., Kubuschok, B., Bockmühl, U., Mueller-Huesmann, H., Klautke, G., Reuter, B., Grün, J. von der, Beutner, D., Büntzel, J., Busch, C-J., Tamaskovics, B.F., Riera Knorrenschild, J., Welslau, M.K., Gauler, T.C., Waldenberger, D., Von der heyde, E.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S625-S626

Erste Real-World Outcome-Daten von Patienten mit SCLC in Deutschland : Daten aus der Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)

Autor: Sebastian, M., Reck, M., Fischer, R., Christoph, D. C., Bernhardt, C., von der Heyde, E., Nusch, A., Ludwig, P., Hipper, A., Hanselmann, J., Medinger, T., Binninger, A., Jänicke, M., Christopoulos, P., Elender, C., Bethge, A., Seese, B., Gauler, Thomas, Waller, C. F.

Poster-Abstract

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=unidue___bib::6a20d03ca46ff928498b9db6e43b7250

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.